A new vaping study by the American-based laboratory and testing facility BioReliance conducted a series of tests comparing the smoke from a king-sized tobacco cigarette to the vapor from a Vype ePen. The study was funded by the Big Tobacco retailer British American Tobacco, and the results indicate that the levels of carcinogens in e-cig vapor are virtually non-existent.
The cigarette used in the study contained home-grown tobacco from the United States and 9.4mg of tar, which meets the International Organisation of Standardisation (ISO) requirements. Meanwhile, the Vype ePen was a closed-system device containing e-liquid of 18mg/ml of nicotine, a replaceable cartridge, and a rechargeable battery system. The BioReliance study is entitled Comparative tumor promotion assessment of e-cigarette and cigarettes using the in vitro Bhas 42 cell transformation assay is readily available for review via Environmental and Molecular Mutagenesis.
Guidelines of the BioReliance vaping study
According to the research, conventional tobacco cigarettes contain a whopping 6,000 different chemicals, 150 of which are known carcinogens of both genotoxic and nongenotoxic classifications. By focusing on the risks of tumor promotion that commonly result from the nongenotoxic varieties, the scientific team from BioReliance discovered that the smoke emissions from the tobacco cigarette contained enormous amounts of cancer-causing agents. Meanwhile, the vapor from the Vype device was virtually carcinogen-free.
“Approximately 150 mg of TPM or ACM were collected on 44 mm Cambridge filter pads (Whatman, Maidstone, UK). The same number of puffs was used to generate enough TPM/ACM from each product for each pad (4 sticks of 3R4F (10 puffs/stick) and 40 puffs from the e-cigarette). Pads were weighed before and after TPM/ACM collection. Dimethylsulphoxide (DMSO) was used to elute the TPM or ACM from the pads to a stock concentration of 24 mg/mL. Additional pads were prepared in parallel for determination of water and nicotine content in the TPM/ACM. A single batch each of 3R4F TPM and e-cigarette ACM was created for all experiments, by pooling the extracts from a number of pads. The extracts were stored in single-use volumes at −80°C. The samples were shipped on dry ice to the testing facility and stored at ≤–60°C until required.”
According to the researchers from BioReliance, this is the first vaping study of its kind which focuses on the potential for cell transformation (tumor production) via a comparative analysis of e-cig vapor to combustible cigarette smoke. The scientists also acknowledge the possible perception of a conflict of interest since the study was funded by a member of Big Tobacco. However, they stand by their findings that e-cigs may “have reduced tumor promoter activity compared to conventional cigarettes.”
Related Article: BOGUS ‘STUDY’ CLAIMS E-CIGS RELEASE TWO NEW CANCER-CAUSING CHEMICALS
Share this post
The opinions expressed in this article are those of the author's and do not necessarily represent the viewpoints, policy or company position of Vapes.com, the rest of our staff, and/or any/all contributors to this site.